{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:26:26Z","timestamp":1793769986801,"version":"4.6.1"},"reference-count":172,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science, Technological Development and Innovation, Republic of Serbia through a Grant Agreement with University of Belgrade, Faculty of Pharmacy","award":["451-03-47\/2023-01\/ 200161"],"award-info":[{"award-number":["451-03-47\/2023-01\/ 200161"]}]},{"name":"Ministry of Science, Technological Development and Innovation, Republic of Serbia through a Grant Agreement with University of Belgrade, Faculty of Pharmacy","award":["IP-2019-04-6048"],"award-info":[{"award-number":["IP-2019-04-6048"]}]},{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","award":["451-03-47\/2023-01\/ 200161"],"award-info":[{"award-number":["451-03-47\/2023-01\/ 200161"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","award":["IP-2019-04-6048"],"award-info":[{"award-number":["IP-2019-04-6048"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"name":"COST Action CA16231 European Network of Vaccine Adjuvants (ENOVA)","award":["451-03-47\/2023-01\/ 200161"],"award-info":[{"award-number":["451-03-47\/2023-01\/ 200161"]}]},{"name":"COST Action CA16231 European Network of Vaccine Adjuvants (ENOVA)","award":["IP-2019-04-6048"],"award-info":[{"award-number":["IP-2019-04-6048"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Ever since the development of the first vaccine, vaccination has had the great impact on global health, leading to the decrease in the burden of numerous infectious diseases. However, there is a constant need to improve existing vaccines and develop new vaccination strategies and vaccine platforms that induce a broader immune response compared to traditional vaccines. Modern vaccines tend to rely on certain nanotechnology platforms but are still expected to be readily available and easy for large-scale manufacturing and to induce a durable immune response. In this review, we present an overview of the most promising nanoadjuvants and nanoparticulate delivery systems and discuss their benefits from tehchnological and immunological standpoints as well as their objective drawbacks and possible side effects. The presented nano alums, silica and clay nanoparticles, nanoemulsions, adenoviral-vectored systems, adeno-associated viral vectors, vesicular stomatitis viral vectors, lentiviral vectors, virus-like particles (including bacteriophage-based ones) and virosomes indicate that vaccine developers can now choose different adjuvants and\/or delivery systems as per the requirement, specific to combatting different infectious diseases.<\/jats:p>","DOI":"10.3390\/vaccines11071172","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:43:30Z","timestamp":1688085810000},"page":"1172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines"],"prefix":"10.3390","volume":"11","author":[{"given":"Brankica","family":"Filipi\u0107","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4457","authenticated-orcid":false,"given":"Ivana","family":"Panteli\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6534-0418","authenticated-orcid":false,"given":"Ines","family":"Nikoli\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia"},{"name":"Section of Pharmaceutical Sciences, University of Geneva, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-0900","authenticated-orcid":false,"given":"Dragomira","family":"Majhen","sequence":"additional","affiliation":[{"name":"Division of Molecular Biology, Ru\u0111er Bo\u0161kovi\u0107 Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zorica","family":"Stoji\u0107-Vukani\u0107","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6236-9730","authenticated-orcid":false,"given":"Sne\u017eana","family":"Savi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5525-0109","authenticated-orcid":false,"given":"Danina","family":"Kraji\u0161nik","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lemoine, C., Thakur, A., Kraji\u0161nik, D., Guyon, R., Longet, S., Razim, A., G\u00f3rska, S., Pantelic, I., Ilic, T., and Nikolic, I. (2020). Technological Approaches for Improving Vaccination Compliance and Coverage. Vaccines, 8.","DOI":"10.3390\/vaccines8020304"},{"key":"ref_2","first-page":"103","article-title":"Recent Patents on Nasal Vaccines Containing Nanoadjuvants","volume":"16","author":"Candela","year":"2022","journal-title":"Recent. Adv. Drug. Deliv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2022.08.020","article-title":"From vaccines to nanovaccines: A promising strategy to revolutionize rheumatoid arthritis treatment","volume":"350","author":"Zhang","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113994","DOI":"10.1016\/j.addr.2021.113994","article-title":"Delivering more for less: Nanosized, minimal-carrier and pharmacoactive drug delivery systems","volume":"179","author":"Etter","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yuba, E., Kado, Y., Kasho, N., and Harada, A. (J. Control. Release, 2022). Cationic lipid potentiated the adjuvanticity of polysaccharide derivative-modified liposome vaccines, J. Control. Release, Online ahead of print.","DOI":"10.1016\/j.jconrel.2022.10.016"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jcis.2022.07.022","article-title":"Self-assembled aluminum oxyhydroxide nanorices with superior suspension stability for vaccine adjuvant","volume":"627","author":"Bi","year":"2022","journal-title":"J. Colloid. Interface Sci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Carmona-Ribeiro, A.M. (2021). Supramolecular Nanostructures for Vaccines. Biomimetics, 7.","DOI":"10.3390\/biomimetics7010006"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.coi.2005.05.005","article-title":"Vaccinology at the beginning of the 21st century","volume":"17","author":"Wack","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In Vivo CD4+ T Cell Differentiation and Function: Revisiting the Th1\/Th2 Paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rapaka, R.R., Cross, A.S., and McArthur, M.A. (2021). Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9080820"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1043109","DOI":"10.3389\/fimmu.2023.1043109","article-title":"New-age vaccine adjuvants, their development, and future perspective","volume":"14","author":"Verma","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2174\/1386207323666201218115850","article-title":"Virus as a Nanocarrier for Drug Delivery Redefining Medical Therapeutics\u2014A Status Report","volume":"25","author":"Ojha","year":"2022","journal-title":"Comb. Chem. High. Throughput Screen"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1016\/j.vaccine.2012.08.023","article-title":"Nanovaccinology: The next generation of vaccines meets 21st century materials science and engineering","volume":"30","author":"Mamo","year":"2012","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12951-022-01625-0","article-title":"An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19","volume":"20","author":"Yasamineh","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"ref_17","unstructured":"Schijns, V., and O\u2019Hagan, D. (2017). Immunopotentiators in Modern Vaccines, Academic Press. Chapter 18."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Singh, M. (2007). Vaccine Adjuvants and Delivery Systems, John Wiley & Sons, Inc.","DOI":"10.1002\/9780470134931"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14760584.6.5.685","article-title":"Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation","volume":"6","author":"Hem","year":"2007","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_21","unstructured":"Sheskey, P.J., Cook, W.G., and Cable, C.T. (2017). Handbook of Pharmaceutical Excipients, Pharmaceutical Press. [8th ed.]."},{"key":"ref_22","unstructured":"Plotkin, S.A., Orenstein, W.A., Offit, P.A., and Edwards, K.M. (2018). Plotkin\u2019s Vaccines, Elsevier. Chapter 6."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/hv.3.4.4309","article-title":"Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice","volume":"3","author":"Caulfield","year":"2007","journal-title":"Hum. Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: You might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"NJP Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1208\/s12248-011-9261-1","article-title":"A rational, systematic approach for the development of vaccine formulations","volume":"13","author":"Morefield","year":"2011","journal-title":"AAPS J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5937\/arhfarm1906420K","article-title":"Established and advanced adjuvants in vaccines\u2019 formulation: Mineral adsorbents, nanoparticulate carriers and microneedle delivery systems","volume":"69","year":"2019","journal-title":"Arh. Farm."},{"key":"ref_27","unstructured":"Galazka, A.M., Milstien, J.B., and Zaffran, M. (1998). Thermostability of Vaccines, World Health Organization. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/64980."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jps.10294","article-title":"Stabilization of alum-adjuvanted vaccine dry powder formulations: Mechanism and application","volume":"92","author":"Maa","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jps.22284","article-title":"Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability","volume":"100","author":"Clapp","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2014.01.005","article-title":"Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars","volume":"55","author":"Tonnis","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2015.02.035","article-title":"A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution","volume":"204","author":"Li","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2013.10.032","article-title":"Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles","volume":"173","author":"Li","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fimmu.2012.00406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"Hogenesch","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16719","DOI":"10.1038\/srep16719","article-title":"GPRC6A mediates Alum-induced Nlrp3 inflammasome activation but limits Th2 type antibody responses","volume":"5","author":"Quandt","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coi.2017.06.009","article-title":"No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vac-cines","volume":"47","author":"Mitchell","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0264-410X(02)00166-4","article-title":"Aluminum salts in vaccines--US perspective","volume":"20","author":"Baylor","year":"2002","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOP.0000000000000868","article-title":"Toward precision adjuvants: Optimizing science and safety","volume":"32","author":"Nanishi","year":"2020","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nantod.2019.04.005","article-title":"Designing inorganic nanomaterials for vaccines and immunotherapies","volume":"27","author":"Hess","year":"2019","journal-title":"Nano Today"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1039\/C8CS00028J","article-title":"Tailoring inorganic nanoadjuvants towards next-generation vaccines","volume":"47","author":"Li","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1021\/nn404211j","article-title":"Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles","volume":"7","author":"Sun","year":"2013","journal-title":"ACS Nano"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/1061186X.2018.1428808","article-title":"Uric acid and the vaccine adjuvant activity of aluminum (oxy)hydroxide nanoparticles","volume":"26","author":"Thakkar","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/21691401.2016.1233111","article-title":"Aluminum hydroxide nanoparticles show strong activity to stimulate Th-1 immune response against tuberculosis","volume":"45","author":"Amini","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101445","DOI":"10.1016\/j.nantod.2022.101445","article-title":"Mechanistic understanding of the aspect ratio-dependent adjuvanticity of engineered aluminum oxyhydroxide nanorods in prophylactic vaccines","volume":"43","author":"Liang","year":"2022","journal-title":"Nano Today"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.1021\/acsami.5b00348","article-title":"Phospholipid bilayer-coated aluminum nanoparticles as an effective vaccine adjuvant-delivery system","volume":"7","author":"Wang","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"120960","DOI":"10.1016\/j.biomaterials.2021.120960","article-title":"Engineering aluminum hydroxyphosphate nanoparticles with well-controlled surface property to enhance humoral immune responses as vaccine adjuvants","volume":"275","author":"Liang","year":"2021","journal-title":"Biomaterials"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21697","DOI":"10.1021\/acsami.7b05817","article-title":"Enhanced Immune Adjuvant Activity of Aluminum Oxyhydroxide Nanorods through Cationic Surface Functionalization","volume":"9","author":"Sun","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_48","first-page":"4092","article-title":"Efficient antigen cross-presentation through coating conventional aluminum adjuvant particles with PEI","volume":"13","author":"Ren","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18495435221088374","DOI":"10.1177\/18495435221088374","article-title":"Mesoporous silica nano-adjuvant triggers pro-inflammatory responses in Caco-2\/peripheral blood mononuclear cell (PBMC) co-cultures","volume":"9","author":"Ghasemi","year":"2022","journal-title":"Nanobiomedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.biopha.2018.10.167","article-title":"Mesoporous silica nanoparticles for therapeutic\/diagnostic applications","volume":"109","author":"Jafari","year":"2019","journal-title":"Biomed. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1002\/adma.201205292","article-title":"In vivo bio-safety evaluations and diagnostic\/therapeutic applications of chemically designed mesoporous silica nanoparticles","volume":"25","author":"Chen","year":"2013","journal-title":"Adv. Mater."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/adma.201104763","article-title":"Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery","volume":"24","author":"Tang","year":"2012","journal-title":"Adv. Mater."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.2147\/IJN.S154743","article-title":"Properties and applications of nanoparticle\/microparticle conveyors with adjuvant characteristics suitable for oral vaccination","volume":"13","author":"Zhang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/smll.201300012","article-title":"Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice","volume":"9","author":"Mahony","year":"2013","journal-title":"Small"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1039\/c3nr00357d","article-title":"Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery","volume":"5","author":"Mody","year":"2013","journal-title":"Nanoscale"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1016\/j.vaccine.2010.09.087","article-title":"Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15","volume":"28","author":"Carvalho","year":"2010","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijpharm.2012.06.028","article-title":"Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: Effect of silica architecture on immunological properties","volume":"436","author":"Wang","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0394632016656192","article-title":"Enhancement of ovalbumin-specific Th1, Th2, and Th17 immune responses by amorphous silica nanoparticles","volume":"29","author":"Toda","year":"2016","journal-title":"Int. J. Immunopathol. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1038\/s41598-019-42645-5","article-title":"3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"110763","DOI":"10.1016\/j.micromeso.2020.110763","article-title":"Assessing the efficiency of SBA-15 as a nanocarrier for diphtheria anatoxin","volume":"312","author":"Rasmussen","year":"2021","journal-title":"Microporous Mesoporous Mater."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.nano.2016.06.003","article-title":"Nanostructured SBA-15 silica: An effective protective vehicle to oral hepatitis B vaccine immunization","volume":"12","author":"Scaramuzzi","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fchem.2019.00290","article-title":"Mesoporous silica nanoparticles for protein protection and delivery","volume":"7","author":"Xu","year":"2019","journal-title":"Front. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"214309","DOI":"10.1016\/j.ccr.2021.214309","article-title":"Chemically engineered mesoporous silica nanoparticles-based intelligent delivery systems for theranostic applications in multiple cancerous\/non-cancerous diseases","volume":"452","author":"Zhou","year":"2022","journal-title":"Coord. Chem. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1704465","DOI":"10.1002\/smll.201704465","article-title":"Clay nanoparticles elicit long-term immune responses by forming biodegradable depots for sustained antigen stimulation","volume":"14","author":"Chen","year":"2018","journal-title":"Small"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Govea-Alonso, D.O., Garc\u00eda-Soto, M.J., Betancourt-Mendiola, L., Padilla-Ortega, E., Rosales-Mendoza, S., and Gonz\u00e1lez-Ortega, O. (2022). Nanoclays: Promising Materials for Vaccinology. Vaccines, 10.","DOI":"10.3390\/vaccines10091549"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Delville, M.H., and Taubert, A. (2017). Hybrid Organic\u2013Inorganic Interfaces: Towards Advanced Functional Materials, Wiley-VCH Verlag GmbH & Co. KgaA.","DOI":"10.1002\/9783527807130"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1002\/ejic.201200579","article-title":"Lipid-based bio-nanohybrids for functional stabilisation of influenza vaccines","volume":"32","author":"Wicklein","year":"2012","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14760584.2017.1306440","article-title":"An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators","volume":"16","author":"Chauhan","year":"2017","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"214345","DOI":"10.1016\/j.ccr.2021.214345","article-title":"Metal-based nano-vaccines for cancer immunotherapy","volume":"455","author":"Li","year":"2022","journal-title":"Coord. Chem. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cis.2003.10.023","article-title":"Formation and stability of nano-emulsions","volume":"108\u2013109","author":"Tadros","year":"2004","journal-title":"Adv. Colloid. Int. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bonferoni, M.C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., and Giunchedi, P. (2019). Nanoemulsions for \u201cNose-to-Brain\u201d Drug Delivery. Pharmaceutic, 11.","DOI":"10.3390\/pharmaceutics11020084"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijpharm.2017.05.051","article-title":"Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances","volume":"533","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"105135","DOI":"10.1016\/j.ejps.2019.105135","article-title":"Microstructure and biopharmaceutical performances of curcumin-loaded low-energy nanoemulsions containing eucalyptol and pinene: Terpenes\u2019 role overcome penetration enhancement effect?","volume":"142","author":"Nikolic","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2217\/nnm-2018-0088","article-title":"Nanoemulsions in drug delivery: Formulation to medical application","volume":"13","author":"Tayeb","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_75","unstructured":"The European Medicines Agency, Committee for Medicinal Products for Human Use (2023, March 11). Guideline on Adjuvants in Vaccines for Human Use. Available online: https:\/\/www.ema.europa.eu\/en\/adjuvants-vaccines-human-use."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59\u00ae adjuvant: A phoenix that arose from the ashes","volume":"12","author":"Ott","year":"2013","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","article-title":"Unmet needs in modern vaccinology: Adjuvants to improve the immune response","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Rappuoli","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1586\/erv.10.89","article-title":"Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses","volume":"9","author":"Oyewumi","year":"2010","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cei.13287","article-title":"Novel approaches for the design, delivery and administration of vaccine technologies","volume":"196","author":"Wallis","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/S0264-410X(00)00498-9","article-title":"Adjuvants designed for veterinary and human vaccines","volume":"19","author":"Aucouturier","year":"2001","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1002\/jps.23311","article-title":"AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method","volume":"101","author":"Klucker","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/erv.09.5","article-title":"Emulsion-based adjuvants for influenza vaccines","volume":"8","author":"Vogel","year":"2009","journal-title":"Expert. Rev. Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/meth.1999.0832","article-title":"Squalene and squalane emulsions as adjuvants","volume":"19","author":"Allison","year":"1999","journal-title":"Methods"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.3390\/molecules14093286","article-title":"Squalene emulsions for parenteral vaccine and drug delivery","volume":"14","author":"Fox","year":"2009","journal-title":"Molecules"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rappuoli, R., and Del Giudice, G. (2008). Influenza Vaccines for the Future, Birkhauser Basel. Chapter 10.","DOI":"10.1007\/978-3-7643-8371-8"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells","volume":"180","author":"Seubert","year":"2008","journal-title":"J. Immunol."},{"key":"ref_88","first-page":"1017","article-title":"Melanoma vaccines: Mixed past, promising future","volume":"94","author":"Lee","year":"2014","journal-title":"Surg. Clin."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/14760584.2.3.353","article-title":"Melacine\u00ae: An allogeneic melanoma tumor cell lysate vaccine","volume":"2","author":"Sosman","year":"2003","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/ppul.25512","article-title":"Narcolepsy in Children: Sleep disorders in children, A rapidly evolving field seeking consensus","volume":"57","author":"Dye","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_93","first-page":"792","article-title":"Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses","volume":"35","author":"Mirzaee","year":"2022","journal-title":"Biomed. Env. Sci."},{"key":"ref_94","unstructured":"(2023, March 15). Properties of MontanideTM Range of Ingredients. Available online: https:\/\/www.seppic.com\/en\/montanide_pharma."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1128\/JVI.00549-10","article-title":"A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets","volume":"84","author":"Bodewes","year":"2010","journal-title":"J. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"100126","DOI":"10.1016\/j.jvacx.2021.100126","article-title":"Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice [published online ahead of print, 2021 Nov 5]","volume":"9","author":"Lai","year":"2021","journal-title":"Vaccine X"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.01.053","article-title":"Stability of collapse lyophilized influenza vaccine formulations","volume":"483","author":"Anamur","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.02.047","article-title":"Freeze-drying of emulsified systems: A review","volume":"503","author":"Marcelino","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11705-021-2123-1","article-title":"Optimising the oil phases of aluminium hydrogel-stabilised emulsions for stable, safe and efficient vaccine adjuvant","volume":"16","author":"Yuan","year":"2022","journal-title":"Front. Chem. Sci. Eng."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.1016\/j.vaccine.2011.08.089","article-title":"Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions","volume":"29","author":"Fox","year":"2011","journal-title":"Vaccine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2217\/nnm-2021-0360","article-title":"Nanotechnology in adjuvants and vaccine development: What should we know?","volume":"16","author":"Assis","year":"2021","journal-title":"Nanomedicine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41541-021-00418-0","article-title":"\u201cWorld in motion\u201d\u2014Emulsion adjuvants rising to meet the pandemic challenges","volume":"6","author":"Lodaya","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Andreadakis","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_105","unstructured":"(2023, April 04). European Medicines Agency, VidPrevtyn Beta Product Information File. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vidprevtyn-beta#product-information-section."},{"key":"ref_106","unstructured":"Glaxo Smith Kline (2023, April 04). Press. Release. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/sanofi-and-gsk-s-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-ec\/."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41590-022-01168-4","article-title":"Making innate sense of mRNA vaccine adjuvanticity","volume":"23","author":"Kobiyama","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1080\/21645515.2015.1046660","article-title":"Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants","volume":"11","author":"Iyer","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1021\/nn3057005","article-title":"Gold nanoparticles as a vaccine platform: Influence of size and shape on immunological responses in vitro and in vivo","volume":"7","author":"Niikura","year":"2013","journal-title":"ACS Nano"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"11520","DOI":"10.1038\/s41598-019-47885-z","article-title":"The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and-activation","volume":"9","author":"Shah","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.2217\/nnm.14.193","article-title":"The impact of size on particulate vaccine adjuvants","volume":"9","author":"Shah","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2015.10.003","article-title":"Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule","volume":"95","author":"Somiya","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Fan, J., Jin, S., Gilmartin, L., Toth, I., Hussein, W.M., and Stephenson, R.J. (2022). Advances in Infectious Disease Vaccine Adjuvants. Vaccines, 10.","DOI":"10.3390\/vaccines10071120"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Petkar, K.C., Patil, S.M., Chavhan, S.S., Kaneko, K., Sawant, K.K., Kunda, N.K., and Saleem, I.Y. (2021). An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery. Pharmaceutics, 27.","DOI":"10.3390\/pharmaceutics13040455"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Luiz, M.T., Dutra, J.A.P., Tofani, L.B., de Ara\u00fajo, J.T.C., Di Filippo, L.D., Marchetti, J.M., and Chorilli, M. (2022). Targeted Liposomes: A Nonviral Gene Delivery System for Cancer Therapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040821"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/wnan.119","article-title":"Viral nanoparticles and virus-like particles: Platforms for contemporary vaccine design","volume":"3","author":"Plummer","year":"2011","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1016\/j.vaccine.2011.06.071","article-title":"Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8\u03b1+ dendritic cell subset","volume":"29","author":"Suleman","year":"2011","journal-title":"Vaccine"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.1128\/jvi.71.10.7960-7962.1997","article-title":"Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D","volume":"71","author":"Manning","year":"1997","journal-title":"J. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/JVI.80.6.2621-2630.2006","article-title":"Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1","volume":"80","author":"Kuck","year":"2006","journal-title":"J. Virol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis699","article-title":"Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines","volume":"207","author":"Ploquin","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"673699","DOI":"10.3389\/fimmu.2021.673699","article-title":"Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?","volume":"2021","author":"Zhan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression","volume":"50","author":"Fuchs","year":"2019","journal-title":"Immunity"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1080\/14760584.2021.1988854","article-title":"Use of lentiviral vectors in vaccination","volume":"20","author":"Ku","year":"2021","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","article-title":"Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models","volume":"29","author":"Ku","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-020-0186-5","article-title":"Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques","volume":"5","author":"Blasi","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Coutant, F., Sanchez David, R.Y., F\u00e9lix, T., Boulay, A., Caleechurn, L., Souque, P., Thouvenot, C., Bourgouin, C., Beignon, A.S., and Charneau, P. (2012). A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048644"},{"key":"ref_142","first-page":"1772","article-title":"Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus","volume":"28","author":"Ku","year":"2020","journal-title":"Molecules"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138920372005190327120752","article-title":"Clinical applications of virus-like particles: Opportunities and challenges","volume":"20","author":"Yang","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-M\u00e9ndez, J.L., Vazquez-Duhalt, R., Hern\u00e1ndez, L.R., S\u00e1nchez-Arreola, E., and Bach, H. (2022). Virus-like Particles: Fundamentals and Biomedical Applications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158579"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Qian, C., Liu, X., Xu, Q., Wang, Z., Chen, J., Li, T., Zheng, Q., Yu, H., Gu, Y., and Li, S. (2020). Recent Progress on the Versatility of Virus-Like Particles. Vaccines, 8.","DOI":"10.3390\/vaccines8010139"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/2181057a0","article-title":"Particles associated with Australia antigen in the sera of patients with leukaemia, Down\u2019s Syndrome and hepatitis","volume":"218","author":"Bayer","year":"1968","journal-title":"Nature"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: Host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12985-018-0970-2","article-title":"Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope","volume":"15","author":"Metz","year":"2018","journal-title":"Virol. J."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Perotti, M., and Perez, L. (2019). Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV. Viruses, 12.","DOI":"10.3390\/v12010035"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Mohsen, M.O., Gomes, A.C., and Vogel, M. (2018). Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Vaccines, 6.","DOI":"10.3390\/vaccines6030037"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11882-018-0827-1","article-title":"Virus-like particles as carrier systems to enhance immunomodulation in allergen immunotherapy","volume":"18","author":"Anzaghe","year":"2018","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs","volume":"11","author":"Vaca","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"790121","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J. Immunol. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Peabody, D.S., Peabody, J., Bradfute, S.B., and Chackerian, B. (2021). RNA Phage VLP-Based Vaccine Platforms. Pharmaceuticals, 4.","DOI":"10.3390\/ph14080764"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-030-45885-0_13","article-title":"ssRNA Phages: Life Cycle, Structure and Applications","volume":"30","author":"Tars","year":"2020","journal-title":"Biocommunication Phages"},{"key":"ref_159","first-page":"6019","article-title":"Novel ssRNA phage VLP platform for displaying foreign epitopes by genetic fusion","volume":"27","year":"2020","journal-title":"Vaccine"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Palma, M. (2023). Aspects of Phage-Based Vaccines for Protein and Epitope Immunization. Vaccines, 11.","DOI":"10.3390\/vaccines11020436"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Tumban, E., Peabody, J., Peabody, D.S., and Chackerian, B. (2011). A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023310"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1568026621666210618145411","article-title":"Chimeric Virus-like Particles of Universal Antigen Epitopes of Coronavirus and Phage Q\u03b2 Coat Protein Trigger the Production of Neutralizing Antibodies","volume":"5","author":"Guo","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00705-019-04216-x","article-title":"Foot-and-mouth disease vaccines: Recent updates and future perspectives","volume":"164","author":"Kamel","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/eji.201041225","article-title":"Universal vaccine against influenza virus: Linking TLR signaling to anti-viral protection","volume":"42","author":"Schmitz","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Liu, X., Chang, X., Rothen, D., Derveni, M., Krenger, P., Roongta, S., Wright, E., Vogel, M., Tars, K., and Mohsen, M.O. (2021). AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate. Vaccines, 19.","DOI":"10.3390\/vaccines9040403"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40629-018-0074-y","article-title":"Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases","volume":"27","author":"Klimek","year":"2018","journal-title":"Allergo J. Int."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijbiomac.2021.04.005","article-title":"Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review","volume":"182","author":"Asadi","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","article-title":"The virosome concept for influenza vaccines","volume":"23","author":"Huckriede","year":"2005","journal-title":"Vaccine"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"key":"ref_170","first-page":"107453","article-title":"Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharm."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Pinski, A.N., and Messaoudi, I. (2020). To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. Microorganisms, 25.","DOI":"10.3390\/microorganisms8101473"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Nemirov, K., Bourgine, M., Anna, F., Wei, Y., Charneau, P., and Majlessi, L. (2023). Lentiviral Vectors as a Vaccine Platform against Infectious Diseases. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030846"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/7\/1172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:31Z","timestamp":1760126611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/7\/1172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":172,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["vaccines11071172"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11071172","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}